中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (34): 6325-6330.doi: 10.3969/j.issn.1673-8225.2011.34.014

• 药物控释材料 drug delivery materials • 上一篇    下一篇

包载人基质金属蛋白酶组织抑制因子1重组腺病毒微球的制备及其表征

夏  冬1，贺  凯2，李显蓉1，徐  亮1   

  1. 泸州医学院附属医院，1普外科， 2肝胆外科，四川省泸州市 646000
  • 收稿日期:2011-04-06 修回日期:2011-06-11 出版日期:2011-08-20 发布日期:2011-08-20
  • 通讯作者: 徐亮，硕士，教授，泸州医学院附属医院普外科，四川省泸州市 646000 juliahhy@yahoo.com.cn
  • 作者简介:夏冬☆，男，1975年生，四川省南充市人，汉族， 2006年四川大学毕业，博士，副教授，主要从事普通外科的基础与临床研究。 xiadong19750411@163.com
  • 基金资助:

    课题受四川省教育厅课题(2006B108)和四川省卫生厅课题(090210)资助。

Preparation and characterization of microspheres encapusulating recombinant adenovirus with human tissue inhibitors of matrix metalloproteinase-1 gene

Xia Dong1, He Kai2, Li Xian-rong1, Xu Liang1   

  1. 1Department of General Surgery, Affiliated Hospital of Luzhou Medical College, Luzhou 646000, Sichuan Province, China; 2Department of Hepatobiliary Surgery, Affiliated Hospital of Luzhou Medical College, Luzhou  646000, Sichuan Province, China
  • Received:2011-04-06 Revised:2011-06-11 Online:2011-08-20 Published:2011-08-20
  • Contact: Xu Liang, Master, Professor, Department of General Surgery, Affiliated Hospital of Luzhou Medical College, Luzhou 646000, Sichuan Province, China juliahhy@yahoo.com.cn
  • About author:Xia Dong☆, M.D., Associate professor, Department of General Surgery, Affiliated Hospital of Luzhou Medical College, Luzhou 646000, Sichuan Province, China xiadong19750411@163.com
  • Supported by:

    the Education Department Foundation of Sichuan Province, No. 2006B108*; the Health Department Foundation of Sichuan Province, No. 090210*

PDF

367

摘要：

背景：高分子载药微球可控释药物，易于实现靶向给药，是近年发展快速的的新剂型。
目的：制备携带人基质金属蛋白酶组织抑制因子1的重组腺病毒微球，并进行表征分析。
方法：采用可降解的生物材料聚乳酸-聚乙烯醇包被携带人基质金属蛋白酶组织抑制因子1基因的重组腺病毒制成微球，体外检测其形态大小、包封率、载病毒率及释放规律。重组腺病毒微球感染人肝癌细胞株HepG2，检测感染效率，明胶酶谱分析测定微球对HepG2分泌TIMP-1的影响，Western blot检测人基质金属蛋白酶组织抑制因子1蛋白的表达，MTT实验检测细胞增殖率，体外侵袭小室实验检测细胞侵袭力。
结果与结论：构建的包载人基质金属蛋白酶组织抑制因子1重组腺病毒的PELA微球直径约1.965 μm，包封率为60.0%，载病毒率为10.5×108/mg，在120 h内释放病毒量接近60%，总释放时间长于240 h。腺病毒微球感染HepG2细胞，当微球> 10 mg时，感染效率可达90%以上。微球感染HepG2细胞后经Western blot检测可见人基质金属蛋白酶组织抑制因子1蛋白的表达。MTT实验及体外侵袭实验结果均提示重组腺病毒微球对HepG2细胞的体外增殖和侵袭有抑制作用，腺病毒微球组细胞增殖率较低(P < 0.05)，腺病毒微球感染的HepG2细胞体外侵袭力明显降低(P < 0.01)。结果证实，制备的人基质金属蛋白酶组织抑制因子1重组腺病毒微球，高效缓释，可明显抑制肝癌HepG2细胞体外增殖和侵袭。

关键词: 基质金属蛋白酶组织抑制因子, 腺病毒, 微球, 制备, 表征, 肝癌, 组织工程

Abstract:

BACKGROUND: Polymer vehicle microsphere is a new form of medicine developed rapidly in recent years, which can control drug release, prolong the biological half-life of drugs, lessen side effects, and achieve targeted delivery.
OBJECTIVE: To construct the polymer microsphere encapusulating recombinant adenovirus with human tissue inhibitors of matrix metalloproteinase-1 (TIMP-1) gene, and to discuss its characterization.
METHODS: The microsphere was constructed by biodegradable poly-DL-lactide-poly (PELA) encapsulating rAdTIMP-1, the recombinant adenovirus carrying TIMP-1. The morphous, diameter, virus encapusulating and loading rate, and releasing kinetics of the microsphere were determined in vitro. HepG2 cells were infected with the microsphere, then, the efficiency of infection was checked by fluorescent microscope. The production and expression of TIMP-1 was identified by gelatin zymography and Western blotting analysis, and the proliferation and invasiveness were detected by MTT analysis and Boyden Chamber assay, respectively.
RESULTS AND CONCLUSION: The microsphere encapsulating rAdTIMP-1 was successfully constructed and its diameter, encapsulating rate, and virus loads were 1.965 μm, 60.0%, and 10.5×108/mg, respectively. Almost 60% of the viruses were released within 120 hours, and the total releasing time would last more than 240 hours. The resultant microsphere encapsulating rAdTIMP-1 can efficiently infected HepG2 cells with an efficiency of infection about 90%. As a result, the infected HepG2 cells significantly increased their TIMP-1 enzyme activity and the expression of TIMP-1 was detected by Western blot. And the tumor cells’ proliferative activity and invasive ability were significantly inhibited by the microsphere. The resultant medical microsphere, with high-performance and slow-release, can markedly inhibit the in vitro biological behaviors of HepG2 cells, which may pave the way for application in prospective in vitro experiment and further liver cancer comprehensive therapy.

中图分类号: